AbCellera Biologics is a biopharmaceutical company developing antibody-based therapeutics targeting conditions with limited treatment options. The company's pipeline includes ABCL635, a non-hormonal candidate in Phase 2 trials for vasomotor symptoms, and ABCL575, a long-acting monoclonal antibody in Phase 1 development for T-cell-driven autoimmune disorders including atopic dermatitis. AbCellera has established partnerships with major pharmaceutical firms including Eli Lilly, AbbVie, Jazz Pharmaceuticals, Biogen, and Vertex to advance its research in multispecific antibody technology for autoimmune and other diseases.
1Y: 12.27 (+121.1%) · range 2.78–14.82
entry readiness 17 · NOT READY · exit proximity 35
Value area 3.94–11.25 · 15% of 120d volume overhead · clean runway
| Source | Score | Last seen |
|---|---|---|
| trader-sentiment | 0.556 | Oct 15, 2026 |
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -15.09% | +6.47% | 19/20d |
| 40d | -15.09% | +6.47% | 19/40d |